Posted by Michael Wonder on 18 Apr 2023
Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with haemophilia B with inhibitors
17 April 2023 - New treatment option for Canadians living with rare and serious X-chromosome linked congenital bleeding disorder
Health Canada has approved Alhemo, the first anti-tissue factor pathway inhibitor and subcutaneous prophylactic treatment for people living with haemophilia B with inhibitors.
